Taysha Gene Therapies, Inc. Common Stock
TSHATaysha Gene Therapies, Inc. is a biotechnology company focused on developing gene therapies for neurodegenerative diseases and monogenic rare disorders. Founded with a mission to deliver transformative treatments, Taysha leverages its proprietary platform to develop innovative viral vector-based therapies aimed at addressing the underlying causes of these conditions. The company collaborates with academic institutions and industry partners to advance its pipeline of potential treatments.
Company News
The global Sandhoff disease treatment market is projected to grow from $260 million in 2024 to $456.42 million by 2034, with a 5.75% CAGR. North America dominates the market, and gene therapy is expected to be a key growth segment for treating this rare genetic disorder.
Taysha Gene Therapies granted five new employees options to purchase 225,000 shares of common stock under their 2023 Inducement Plan, with options vesting over four years at an exercise price of $2.84.
Taysha Gene Therapies granted a new employee an option to purchase 90,000 shares of common stock under their 2023 Inducement Plan, with an exercise price of $2.63 and a 10-year term vesting over four years.
Taysha Gene Therapies announced details for three oral presentations at the 2025 IRSF Rett Syndrome Scientific Meeting, covering updates on its TSHA-102 clinical program for Rett syndrome and a symposium on natural history data.
Taysha Gene Therapies, a clinical-stage biotechnology company, announced the pricing of a public offering of its common stock and pre-funded warrants, expected to raise approximately $200 million.
